Igene Biotechnology Stock Net Income
Fundamental analysis of Igene Biotechnology allows traders to better anticipate movements in Igene Biotechnology's stock price by examining its financial health and performance throughout various phases of its business cycle.
Igene |
Igene Biotechnology Company Net Income Analysis
Igene Biotechnology's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Igene Biotechnology Net Income | (140.75 K) |
Most of Igene Biotechnology's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Igene Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Igene Biotechnology reported net income of (140,747). This is 98.83% lower than that of the Chemicals sector and 100.06% lower than that of the Materials industry. The net income for all United States stocks is 100.02% higher than that of the company.
Igene Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Igene Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Igene Biotechnology could also be used in its relative valuation, which is a method of valuing Igene Biotechnology by comparing valuation metrics of similar companies.Igene Biotechnology is currently under evaluation in net income category among its peers.
Igene Fundamentals
| Return On Asset | -0.0821 | |||
| Operating Margin | (124.22) % | |||
| Current Valuation | 1.1 M | |||
| Shares Outstanding | 1.57 B | |||
| Shares Owned By Institutions | 0.47 % | |||
| Price To Earning | (0.10) X | |||
| Price To Sales | 2.28 X | |||
| Revenue | 3.96 M | |||
| Gross Profit | 1.02 M | |||
| EBITDA | (426.98 K) | |||
| Net Income | (140.75 K) | |||
| Cash And Equivalents | 269.29 K | |||
| Current Ratio | 1.15 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (97.05 K) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 18 | |||
| Beta | -2.8 | |||
| Market Capitalization | 10.96 K | |||
| Total Asset | 4.76 M | |||
| Retained Earnings | (54.86 M) | |||
| Working Capital | 312 K | |||
| Current Asset | 2.44 M | |||
| Current Liabilities | 2.13 M | |||
| Z Score | -15.4 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 4.76 M |
About Igene Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Igene Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Igene Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Igene Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Igene Pink Sheet
Igene Biotechnology financial ratios help investors to determine whether Igene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Igene with respect to the benefits of owning Igene Biotechnology security.